Literature DB >> 9504235

Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility.

M Akashi1, H P Koeffler.   

Abstract

Mutation of the tumor suppressor gene p53 is a molecular genetic event frequently observed in human cancer, and inactivating missense mutations usually are accompanied by the resultant overexpression of mutant p53 protein. In gynecologic cancers, p53 is also often altered; the frequency varies depending on types of cancers and where they develop. Further, human papillomavirus oncoproteins that inactivate p53 and Rb proteins play important roles in the development of several gynecologic cancers. Individuals who are heterozygous for germline mutations of the p53 gene are strongly predisposed to a variety of cancers. The identification of these individuals may have profound value in the future when therapies or chemopreventive agents specific for the p53 alteration are available. The role of p53 tumor suppressor gene in gynecologic cancers and heritable cancer susceptibility syndromes including Li-Fraumeni and Lynch II syndromes is an active and important area of study.

Entities:  

Mesh:

Year:  1998        PMID: 9504235     DOI: 10.1097/00003081-199803000-00024

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  10 in total

1.  Genetic alterations of the WWOX gene in breast cancer.

Authors:  Seda Ekizoglu; Mahmut Muslumanoglu; Nejat Dalay; Nur Buyru
Journal:  Med Oncol       Date:  2011-10-08       Impact factor: 3.064

2.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.

Authors:  Shuting Jia; Wenru Tang; Ying Luo
Journal:  Hepatol Int       Date:  2012-08-03       Impact factor: 6.047

Review 4.  Age-specific oncogenic pathways in head and neck squamous cell carcinoma - are elderly a different subcategory?

Authors:  Martine Froukje van der Kamp; Gyorgy Bela Halmos; Victor Guryev; Peter Laszlo Horvatovich; Ed Schuuring; Bernardus Franciscus Augustinus Maria van der Laan; Bert van der Vegt; Boudewijn Evert Christiaan Plaat; Cornelia Johanna Verhoeven
Journal:  Cell Oncol (Dordr)       Date:  2022-01-11       Impact factor: 6.730

5.  Altered mammary gland development in the p53+/m mouse, a model of accelerated aging.

Authors:  Catherine E Gatza; Melissa Dumble; Frances Kittrell; David G Edwards; Robert K Dearth; Adrian V Lee; Jianming Xu; Daniel Medina; Lawrence A Donehower
Journal:  Dev Biol       Date:  2007-10-12       Impact factor: 3.582

6.  HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.

Authors:  Oguz Ozturk; Emel Canbay; Ozlem T Kahraman; M Fatih Seyhan; Fatih Aydogan; Varol Celik; Cihan Uras
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

7.  Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms.

Authors:  S Sakajiri; N Kawamata; M Egashira; K Mori; K Oshimi
Journal:  Jpn J Cancer Res       Date:  2001-10

8.  Identification of novel high-frequency DNA methylation changes in breast cancer.

Authors:  Jared M Ordway; Muhammad A Budiman; Yulia Korshunova; Rebecca K Maloney; Joseph A Bedell; Robert W Citek; Blaire Bacher; Seth Peterson; Tracy Rohlfing; Jacqueline Hall; Robert Brown; Nathan Lakey; Rebecca W Doerge; Robert A Martienssen; Jorge Leon; John D McPherson; Jeffrey A Jeddeloh
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

Review 9.  Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?

Authors:  Anneke C Blackburn; D Joseph Jerry
Journal:  Breast Cancer Res       Date:  2002-04-18       Impact factor: 6.466

10.  The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.

Authors:  Bre-Anne Fifield; Ingrid Qemo; Evie Kirou; Robert D Cardiff; Lisa Ann Porter
Journal:  Breast Cancer Res       Date:  2019-12-11       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.